News Sentiment

BBOT sentiment intelligence

BridgeBio Oncology Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.56 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

+2.9% over one week, +13.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded by Wall Street Zen to "Sell" Rating

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 2.9% Price confirming higher
Trend fit Trend inactive 13.2% over four weeks
Fair value -16.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 42
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
TradingView 10
Market source 8
MarketBeat 4
Seeking Alpha 3
Investing.com 3
simplywall.st 3
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 13
Analyst action 9
Deals and strategy 6
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
Stock Titan Direct company coverage

BridgeBio Oncology (BBOT) director awarded 31,675 options at $7.73 strike

BridgeBio Oncology Therapeutics director Raymond J. Kelleher was granted 31,675 stock options with an exercise price of $7.73 per share, expiring on June 15, 2036. The options vest in full on the earlier of the first anniversary of the June 16, 2026 grant date or the next Annual

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 06:11
Source
Stock Titan
TradingKey Direct company coverage

BridgeBio Oncology Therapeutics Ord Shs (BBOT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for BridgeBio Oncology Therapeutics Ord Shs (BBOT), highlighting analyst ratings and future growth estimates for EPS and Revenue. Based on ratings from 10 analysts, the stock currently has a "Buy" trend with a target price indicating a s

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

BridgeBio Oncology Therapeutics Ord Shs (BBOT) Institutional Confidence

This article provides details on the institutional confidence in BridgeBio Oncology Therapeutics Ord Shs (BBOT). It lists key institutional shareholders, the number of shares held, and the percentage change in their holdings. The report highlights major investors like Cormorant A

Tone
Positive 60/100
Event
Market update
Published
18 Jun 2026 08:39
Source
TradingKey
TradingView Direct company coverage

Number of shareholders of BridgeBio Oncology Therapeutics, Inc. – NASDAQ:BBOT

This article provides financial information for BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) on TradingView. It displays shareholder data, though the specific values are not presented in the provided text. The page offers an overview of the company's financials, news, doc

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 16:08
Source
TradingView
TradingView Direct company coverage

Technical Analysis of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT)

This article provides a technical analysis of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) using various indicators like moving averages and oscillators. The analysis suggests a "sell" signal for BBOT stock, with stronger sell trends observed over a one-week period. It als

Tone
Negative 31/100
Event
Market update
Published
08 Jun 2026 20:39
Source
TradingView
MarketBeat Direct company coverage

Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026

This article analyzes BridgeBio Oncology Therapeutics (BBOT) by comparing it to five competitors: DigitalBridge Group (DBRG), Four Corners Property Trust (FCPT), Uniti Group (UNIT), InvenTrust Properties (IVT), and Acadian Asset Management (AAMI). The comparisons cover various fa

Tone
Positive 65/100
Event
Market update
Published
26 May 2026 07:09
Source
MarketBeat